Navigate the Ligand Pharmaceuticals, Inc. ($LGND) stock research pages:
- Introduction (valuation, financials, ownership, guidance, helpful links)
- Promacta (eltrombopag) (key asset licensed to GSK - platelet booster for many thrombocytopenia conditions)
- Kyprolis (carfilzomib) (key asset licensed to Amgen - developed by ONXX for multiple myeloma)
- Other Marketed Products (description of assets currently generating royalty revenue)
- Late-stage Pipeline Assets (generally partnered and developed at little to no cost to LGND and represent future royalty sources)
- Early-stage Development Programs (internal and partnered, future "shots on goal" or out-licensing opportunities)
- Acquisitions (Cydex, Metabasis ($MBRX), Pharmacopeia ($PCOP), Neurogen ($NRGN) - complete terms and details)
- Captisol-Cydex (additional info on the formulation technology acquired in 2011 and details on partnerships)
- Discontinued Programs (with >90 biotech and pharma assets in development, not everything works out!)
Inactive or Abandoned ProgramsOn this page you will find a run-down on the programs owned by LGND that are not in active development (based on my research) or have been discontinued for clinical trial failures, deal termination by partners, or other business reasons.
If my assignment of a program to this page in incorrect in your opinion, please drop me an email! Thanks. Use the links at the bottom of the page to navigate to the rest of my research on LGND. |
|
Fosphenytoin
Status: Unknown - abandoned? Source: Cydex
- fosphenytoin IV, IM (Cerebyx): anti-seizure
- reformulation to allow room temperature RT (vials or prefilled bag) vs 4C storage.
- Cydex website lists as ready for 505b2 NDA submission.
- 2006 brand $71m sales, now generic so <$10m total.
- 2 pivotal studies in 90 pts complete (DB crossover bioequivalence, 38 IV, 52 IM pts, FDA req'd monitoring of potenial renal effects), completing NDA docs and seeking partner.
- S1 had said NDA late 2008- assuming CMC data only needed and not more trials.
- combo patent expires 6/12/2018 (2010 10k and 1q2011 10q)
Budesonide/Azelastine combo
Status: Phase 1/2 - Inactive Source: Cydex
- Budesonide/Azelastine (AZN Rhinocort Aqua/ Meda Astelin; water-insoluble steroid/anti-histamine): nasal formulation (unique solution, possibly less steroid dose w/ same bioavilability, faster onset and symptom relief).
- P2 of budesonide alone and combo in allergic rhinitis completed, seeking partner.
- 3/2009 presented data (RDBPC trial, 108 pts, 3 way crossover- combo spray vs cydex bud+Rhinocort Aqua vs placebo spray w/ ragweed pollen in enviromental exposure chamber NCT00940953): Total Nasal Symptoms Score- both arms sig better vs placebo from 20 min to 10 hrs. Faster (10min) onset for captisol combo for itchy nose and sneezing. Total Ocular Symptom Score- both arms sig better than placebo from 40 min to 10 hrs, captisol combo same or numerically better.
- NCT00938613 p2 budesonide only.
- 2008 S1: p2 oral inhalation nebulizer solution trials in UK (lic to Verus in NA for asthma, then sublic to AZN, 2008 gave AZN option to lic for ROW) and spray p2 trials in Canada.
- Bud is 1/2 of symbicort.
- 2010 10k: "other internal pgm awaiting development by LGND or partner" listed as p1 for allergic rhinitis
Vestipitant (GW597599)
Status: pending phase 1? Source: Cydex
- p1 study (NCT01290133) in healthy volunteers listed 2/2011, not yet recruiting by Octagon Res Solutions (Australia) for postoperative nausea and vomiting
CCR1 inhibitor
Status: Preclinical - inactive Source: Internal Ligand
- preclinical for oncology
- 2010 10k: "other internal pgm awaiting devel by LGND or partner"
CRTH2 inhibitor
Status: Preclinical - inactive Source: Internal Ligand
- preclinical for inflammation
- 2010 10k: "other internal pgm awaiting devel by LGND or partner"
Acedasine
Status: Phase 3 (abandoned) Source: Metabasis
- Have undisclosed minority stake in PeriCor who licensed this drug to Merck
- program is abandoned and patent life gone
Navarixin (MK-7123, fka SCH527123 and PS291822)
Status: Discontinued Source: Pharmacopeia
- CXCR2 antagonist, licensed to Merck for pulmonary diseases.
- 4/22/11 MRK pipeline shown in phase 2
- 6/2011 Analyst Day: listed as potential 2015 launch for COPD
- Phase 2 trials started 4q2006, completed COPD trial 10/2008 and asthma 2/2009.
- Phase 2b started 1/2010 in each indication 6/2010 and 10/2010: both ongoing
- COPD: (as of 2/2011: 500 pts fully enrolled for completion 3q2012, very important for value of program- trial involved 1 yr evaluation of pts and is larger so takes much longer than asthma)
- 11/2010: data early 2012, asthma (~100 pts finished but not disclosed), p1 in other indications
- 11/2011 - this program has been dropped from the MRK pipeline chart.
MEDI-528
Status: Discontinued Source: bought from Genaera liquidation trust
- IL-9 targeting antibody sub-cutaneous injectable
- 5/2010 purchased royalty/milestone interest for $2.75m (and then immediately sold 50% interest to investor)
- partnered with AZN/Medimmune.
- In p2b for moderate to severe asthma (1/2011 fully enrolled 320 pt, 2/2011 target completion 3q2011, 0,30,100,300mg every two wks for 26 wks; primary endpt is asthma control questionaire at 92 days).
- 11/2010: AZN not listed in "filing opportunities 2011-2014"
- 2010 10k: complete trial 4q2011
- 9/2011: AZN/MedImmune terminates the license agreement effective 11/30/2011, so apparently they were not impressed wiht the results of the asthma trial.
Aplindore
Status: Phase 2 (likely abandoned) Source: Neurogen
- 10/2008: positive data from p2 trials in RLS (26 pts in-patient- first dose w/ placebo then drug next night, very statistically significant PLMI data so stopped study) and Parkinsons (39 pts in 5 cohorts- 5-6 drug and 2 placebo per group).
- Moved to larger p2 RLS (RDBPC, enrolled 60% of 195 target before terminated 5/2009, placebo and 4 doses, IRLS scale-diff endpt, stat sig upon termination at 0.05 and 0.25 but not 0.1 dose!).
- Partial agonist- data was good but would not differentiate from full agonists already on market for RLS that would be generic at time of launch.
- Larger Parkinson's study was terminated too but had only enrolled 9 pts.
- 10/2010 have had discussions last 6 months, no one wants to start large p3 pgm, some niche interest. 2010 10k: "other internal pgm awaiting devel by LGND or partner"
PS433540
Status: Phase 2 but abandoned Source: Pharmacopeia
- DARA against angiotensin and endothelin receptors.
- 2/2009 positive p2b results in hypertension- seeking partner for future development.
- 10/2010 seeking partner, not in active r&d. CVR on this pgm requires huge payment, hindering a deal, and short patent life. "Pharmacopeia bet the company on this drug and it didnt work out. "
- 2010 10k: "other internal pgm awaiting devel by LGND or partner"
- 12/2011: period during which PCOP shareholders would have received $15m milestone for licensing transaction involving DARA program expired
RG7348 (fka MB11362)
Status: phase 1 (likely abandoned) Source: Metabasis
- lead for HepDirect antiviral nucleoside prodrug technology under fully funded HCV partnership with Hoffman LaRoche.
- Named clinical candidate 2q2009.
- 4/2010: rec'd $6.5m gross milestone for start of p1 - 65% was paid to MBRX CVR holders (see below).
- 11/2010 agreement terminated by Roche w 60 days notice (pipeline pruning)
- 1/2011: would be covered by Chiva deal for China...but not referenced specifically (see below)
Exelixis $EXEL compounds
Status: Preclinical and phase 1 - inactive Source: internal Ligand
- EXEL licensed technology for one p1 candidate (LXR agonist for atherosclerosis- one of 2 compounds against this target is dead- were they both from LGND?) and two preclinical candidates (FXR inhinibitor for dyslipidemia w/ PFE; XL550 mineralocorticoid rec antagonist for metabolic disorders w/ Daiichi-Sankyo) products.
- 12/2010 company is now focused nearly entirely on XL184, suspend or minimal contractual obligations for partnered assets
MK2995
Status: Terminated Source: Neurogen
- VR1 antagonists for acute and chronic pain and cough, fullly funded by Merck.
- Preclinical, plus a backup compound.
- 10/2010 website mentions only pain
- 10/2011: MRK terminated this deal as of 4/2012. MRK cannot pursue this target until 4/2014
Trevana compounds
- 2/2009 formed collaboration to screen and have rights to license resulting compounds, initial research term thru 1/2011.
- 5/2010 ammended, could end early after screening up to 8 targets selected by 8/2010.
- 5/2010: agreement terminated
- "We believe that this agreement was terminated in response to changes in Trevena internal research priorities relating to the subject matter of the research collaboration" (3/31/11 10q)
Use these links to navigate to additional LGND stock research pages:
- Introduction (valuation, financials, ownership, guidance, helpful links)
- Marketed Products (description of assets currently generating royalty revenue)
- Promacta (key asset licensed to GSK - platelet booster for many thrombocytopenia conditions)
- Late-stage Pipeline Assets (Generally partnered and developed at no cost to LGND, represent future royalty sources)
- Captisol Partnerships (Formulation technology acquired from Cydex: generate product sales, milestones, royalties)
- Early-stage Development Programs (internal and partnered, future "shots on goal" or out-licensing opportunities)
- Acquisitions (Cydex, Metabasis $MBRX, Pharmacopeia $PCOP, Neurogen $NRGN - complete terms and details)
- Discontinued Programs (with >50 biotech and pharma assets at any time, not everything works out!)